Underwood D C, Kotzer C J, Bochnowicz S, Osborn R R, Luttmann M A, Hay D W, Torphy T J
Department of Inflammation & Respiratory Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania.
J Pharmacol Exp Ther. 1994 Jul;270(1):250-9.
Selective inhibition of phosphodiesterase (PDE) isozymes has been shown to inhibit inflammatory cell function and relax airway smooth muscle and, thus, may be useful in the therapy of asthma. In guinea pigs sensitized to ovalbumin (OA), the effects of three PDE inhibitors were compared: siguazodan (PDE III selective, IC50 = 0.7 microM), rolipram (PDE IV selective, IC50 = 0.8 microM) and zardaverine (dual PDE III/IV, IC50S = 2.5 microM and 1.1 microM, respectively) against histamine-, leukotriene (LT) D4- and OA-induced bronchospasm in vitro and in vivo. Rolipram or zardaverine (0.1-10 microM), but not siguazodan, inhibited OA-induced contraction of the isolated trachea in a concentration-dependent manner. Rolipram or siguazodan alone (10 microM) were ineffective against histamine- or LTD4-induced contractions. Zardaverine alone (10 microM) or the combination of rolipram and siguazodan (10 microM each) markedly antagonized the contractions elicited by both spasmogens. In anesthesized, ventilated guinea pigs, the i.v. ID50S against OA-induced bronchospasm were: rolipram = 0.2 mg/kg, siguazodan > 10 mg/kg and zardaverine = 2.4 mg/kg. When administered at doses up to 7.5 mg/kg, i.v., rolipram or siguazodan were markedly less effective (i.e., < or = 50% inhibition) than zardaverine (ID50S = 2.4 and 1.7 mg/kg, respectively) at blocking exogenous histamine- or LTD4-induced bronchospasm. However, when administered in combination with siguazodan (5.4 mg/kg, i.v.), rolipram (0.4-5.4 mg/kg) abolished histamine- and LTD4-induced bronchoconstriction. In conscious guinea pigs, zardaverine (5 mg/kg, intragastrically (i.g.) or the combination of rolipram and siguazodan (5 mg/kg each) were substantially more effective than rolipram or siguazodan alone at inhibiting aerosol histamine- or LTD4-induced bronchospasm. In the same animals, rolipram or zardaverine (5 mg/kg, i.g.) but not siguazodan (5 mg/kg, i.g.) markedly inhibited aerosol OA-induced bronchoconstriction. The OA-induced pulmonary eosinophil infiltration in these animals was attenuated by all treatments with zardaverine producing the greatest degree of inhibition. These results indicate that 1) PDE IV inhibitors but not PDE III inhibitors are effective at blocking antigen-induced bronchospasm, 2) compounds that selectively inhibit either PDE III or PDE IV are poor inhibitors of bronchoconstriction elicited by exogenously administered spasmogens, and 3) the combined inhibition of both PDE III and PDE IV isozymes acts in an additive or synergistic manner to inhibit bronchospasm in the guinea pig.
磷酸二酯酶(PDE)同工酶的选择性抑制已被证明可抑制炎症细胞功能并舒张气道平滑肌,因此可能对哮喘治疗有用。在对卵清蛋白(OA)致敏的豚鼠中,比较了三种PDE抑制剂的作用:西呱唑旦(选择性抑制PDE III,IC50 = 0.7微摩尔)、咯利普兰(选择性抑制PDE IV,IC50 = 0.8微摩尔)和扎达维林(双重抑制PDE III/IV,IC50分别为2.5微摩尔和1.1微摩尔),观察它们在体外和体内对组胺、白三烯(LT)D4和OA诱导的支气管痉挛的影响。咯利普兰或扎达维林(0.1 - 10微摩尔),而非西呱唑旦,能以浓度依赖性方式抑制OA诱导的离体气管收缩。单独使用咯利普兰或西呱唑旦(10微摩尔)对组胺或LTD4诱导的收缩无效。单独使用扎达维林(10微摩尔)或咯利普兰与西呱唑旦联合使用(各10微摩尔)可显著拮抗两种致痉剂引起的收缩。在麻醉、通气的豚鼠中,静脉注射时对抗OA诱导支气管痉挛的半数抑制剂量(ID50)分别为:咯利普兰 = 0.2毫克/千克,西呱唑旦 > 10毫克/千克,扎达维林 = 2.4毫克/千克。静脉注射剂量高达7.5毫克/千克时,咯利普兰或西呱唑旦在阻断外源性组胺或LTD4诱导的支气管痉挛方面明显不如扎达维林有效(ID50分别为2.4和1.7毫克/千克)。然而,当与西呱唑旦(静脉注射5.4毫克/千克)联合使用时,咯利普兰(0.4 - 5.4毫克/千克)可消除组胺和LTD4诱导的支气管收缩。在清醒豚鼠中,扎达维林(5毫克/千克,灌胃)或咯利普兰与西呱唑旦联合使用(各5毫克/千克)在抑制雾化组胺或LTD4诱导的支气管痉挛方面比单独使用咯利普兰或西呱唑旦有效得多。在同一动物中,咯利普兰或扎达维林(5毫克/千克,灌胃)可显著抑制雾化OA诱导的支气管收缩,而西呱唑旦(5毫克/千克,灌胃)则无效。扎达维林的所有处理均可减轻这些动物中OA诱导的肺嗜酸性粒细胞浸润,其抑制程度最大。这些结果表明:1)PDE IV抑制剂而非PDE III抑制剂可有效阻断抗原诱导的支气管痉挛;2)选择性抑制PDE III或PDE IV的化合物对外源性致痉剂引起的支气管收缩抑制作用较差;3)联合抑制PDE III和PDE IV同工酶在豚鼠中以相加或协同方式抑制支气管痉挛。